Sell raloxifene hydrochloride @China (Mainland)

Alias: RALOXIFENE HCL; ly156758; KEOXIFENE;KEOXIFENE HYDROCHLORIDE;LY 139481;AKOS 92138

Product Details:

Place of Origin: China

Certification: ISO9001

Brand:YuanCheng

Payment & Shipping Terms:

Minimum Order Quantity:1kg

Supply Ability:500kg/month

Delivery Time:within 24 hours after payment

Payment Terms:Western Union, MoneyGram, T/T

Package:25kg/cardboad drum  

Appearance:light yellow

Product Description:

CAS: 82640-04-8

M.F.: C28H28ClNO4S

M.W. :510.04

Purity:99.8%

M.P.: 250-253°C

M.S.:

 

EVISTA (raloxifene hydrochloride) is an estrogen agonist/antagonist, commonly referred to as a selective estrogen receptor modulator (SERM) that belongs to the benzothiophene class of compounds

The chemical designation is methanone, [6-hydroxy-2-(4-hydroxyphenyl)benzo[b]thien-3-yl]-[4-[2-(1-piperidinyl)ethoxy]phenyl]-, hydrochloride. Raloxifene hydrochloride (HCl) has the empirical formula C28H27NO4S.HCl, which corresponds to a molecular weight of 510.05. Raloxifene HCl is an off-white to pale-yellow solid that is very slightly soluble in water.

EVISTA (raloxifene) is supplied in a tablet dosage form for oral administration. Each EVISTA tablet contains 60 mg of raloxifene HCl, which is the molar equivalent of 55.71 mg of free base. Inactive ingredients include anhydrous lactose, carnauba wax, crospovidone, FD&C Blue No. 2 aluminum lake, hypromellose, lactose monohydrate, magnesium stearate, modified pharmaceutical glaze, polyethylene glycol, polysorbate 80, povidone, propylene glycol, and titanium dioxide.

Usage:

Reduction in the incidence of invasive breast cancer in postmenopausal women with osteoporosis.

in 2006, the National Cancer Institute announced that raloxifene was as effective as tamoxifen in reducing the incidence of breast cancer in postmenopausal women at increased risk,